A behind-the-scenes federal payment has quietly held down what many Medicare beneficiaries pay for stand-alone drug coverage over the past two years. That support is scheduled to expire at the end of 2026 and will not carry into the next plan year. The change is aimed at one segment of the Medicare population, and its effect will range from a few dollars a month to something more noticeable, depending on the plan and where a person lives.
What the Part D Premium Stabilization Demonstration did
The support at issue is the Medicare Part D Premium Stabilization Demonstration, a voluntary program that insurers offering stand-alone prescription drug plans could opt into. It began in the 2025 plan year, after changes from the Inflation Reduction Act reshaped the Part D benefit and introduced the risk of sharp swings in what plans charged. The demonstration was designed to smooth that volatility, cushioning premiums while insurers adjusted to the new rules, at an estimated cost of $9.8 billion across 2025 and 2026.
Stand-alone drug plans are the coverage bought by beneficiaries who stay in Original Medicare and add a separate Part D plan, as distinct from those who get drug coverage bundled inside a Medicare Advantage plan. The demonstration steadied the premiums on those stand-alone plans specifically, which is why its expiration matters most to that group rather than to the Medicare drug-benefit population as a whole.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Why CMS is ending it and how much premiums may rise
The Centers for Medicare and Medicaid Services decided the temporary cushion has done its job and will let it lapse on December 31, 2026 rather than renew it for 2027. The agency’s reasoning is that insurers now have two years of experience pricing Part D plans under the reworked benefit and can set premiums without the extra support. CMS Administrator Mehmet Oz said most beneficiaries would see premiums rise by less than $10 a month as a result, and that some enrollees could actually pay less.
The demonstration always carried an expiration date rather than a permanent guarantee, which is part of why CMS has cast the wind-down as the end of a temporary measure rather than a benefit cut. It ran for two plan years, 2025 and 2026, precisely the stretch when insurers had the least data on how the redesigned Part D benefit would behave. By the 2027 plan year, the agency argues, that uncertainty has largely resolved, and the roughly $9.8 billion spent over the two years was intended to bridge the transition rather than to hold premiums down indefinitely.
That framing sets expectations for the typical enrollee, but an average masks a spread. Because premiums vary by plan and region, a stand-alone drug plan that leaned heavily on the demonstration could post a larger increase than the modest figure CMS cites, while another plan might change little. The end of the subsidy does not set premiums directly; it removes a backstop, leaving each insurer to price its 2027 plan on its own, which is why outcomes will differ from one plan to the next.
Who feels the change, and what stays in place
The enrollees exposed to the shift are those in stand-alone prescription drug plans, a group that accounts for a substantial share of Part D enrollment. Beneficiaries who get their drug coverage through a Medicare Advantage plan are not the focus of this particular change, since the demonstration applied to the stand-alone market. For those who are affected, the fall enrollment period is the moment to compare 2027 premiums across available plans rather than let a current plan renew automatically.
The change also arrives while Part D premiums were already in flux from the underlying benefit redesign, which can make it hard for an enrollee to separate the effect of the expiring demonstration from other year-to-year movement. What a beneficiary will actually see is a single premium figure on the 2027 plan documents, not a line item labeled for the lost subsidy. That is why comparing the full slate of available stand-alone plans, rather than judging one plan’s increase in isolation, is the step that reveals whether a better-priced option exists.
Importantly, the core drug-benefit improvements from the Inflation Reduction Act are not going anywhere. The annual cap on out-of-pocket drug spending, the limit on insulin costs, and no-cost recommended vaccines all remain in effect. What ends is the temporary premium cushion layered on top of those reforms, not the reforms themselves, a distinction that keeps the change from being as sweeping as an expiring subsidy might sound.
For a retiree budgeting a year ahead, the practical takeaway is to read the 2027 premium on any stand-alone drug plan carefully and weigh it against alternatives, because the number that arrives this fall will reflect pricing without the stabilization payment behind it. Programs that help lower Part D costs continue to exist for beneficiaries with limited income, and those supports are unaffected by the demonstration’s end.
Whether the expiration lands as a minor line-item adjustment or a meaningful jump will not be settled until insurers publish their 2027 premiums and enrollees can see the actual figures side by side. The government’s own estimate points to a modest change for most, but the design of the wind-down guarantees uneven results, and the enrollees in stand-alone drug plans are the ones who will find out first when their notices arrive.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
